Navigation Links
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
Date:6/7/2008

he combination compared to 6.1 percent with TriLipix 135mg monotherapy.

Patients treated with the combination of TriLipix 135mg and rosuvastatin 20mg had an increase in HDL of 17.6 percent and decrease in triglycerides of 42.4 percent compared to an HDL increase of 12.2 percent and triglyceride decrease of 26.8 percent with rosuvastatin 20mg alone. LDL decreased 37.4 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.

"New treatment options are critical given that a substantial number of patients are not achieving treatment goals for their three key lipids," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott. "Abbott has built a robust clinical program to support TriLipix to provide physicians and patients with as much data as possible to help them evaluate this potential new therapy."

About the TriLipix Clinical Trial Program

The efficacy and safety of TriLipix in combination with the three most commonly prescribed statins -- rosuvastatin, atorvastatin and simvastatin -- were evaluated in three randomized, multi-center, double-blind, controlled, 12-week Phase III studies, totaling 2,698 patients with mixed dyslipidemia.

These studies, along with a 52-week long-term safety and efficacy open-label extension study of 1,911 patients, represent the largest program to date examining a fibrate in combination with statins. More than 2,200 patients were treated with TriLipix alone and in combination with statins across these four studies.

The primary data for TriLipix combined with statins were presented at scientific forums earlier this year.

About TriLipix (ABT-335)

TriLipix is an investigational new fenofibric acid molecule, currently in clinical development for treating patients with unhealthy lipid levels, including LDL cholesterol, triglycerides and HDL cholesterol. A New Drug Application (NDA) for TriLipix for use as monotherapy and in comb
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
2. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
3. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
4. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
5. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
6. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
7. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
8. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
11. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from ... China,s orthopedic instrument industry has seen ... rising from 3.28 billion yuan in 2006 to 9.85 ...
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Through Joint Venture Between Bristol-Myers Squibb and ... Its Kind in HIV Treatment -, PRINCETON, N.J. ... Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 mg/emtricitabine ... commercialization in the,27 countries of the European Union, as ...
... novel combination of drugs was,able to completely eradicate ... for the effective treatment of patients with advanced,metastatic ... University,School of Medicine presented the results of a ... pulmonary metastases in female SCID,mice., Paclitaxel is ...
Cached Medicine Technology:European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9New Drug Combination is Able to Eradicate Breast Metastases in Mice 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2
... MIAMI, Sept. 11 Bupa,s ... a leading international healthcare company --,announced today the launch ... a deprived community in Ecuador where many families survive ... employees from around the globe will,travel to Ecuador until ...
... , DETROIT, Sept. 11 Blue Cross ... interim policy to automatically cover the cost of administration of the ... and individual coverage during the 2009-2010 flu season--unless a group chooses ... The Blues also announced that it will enable larger ...
... , , , ... magazine has ranked SoftLight Development, Inc. (SLD) NO. 643 on ... nation,s fastest-growing private companies. The list represents the most comprehensive ... entrepreneurs. Consumer electronics maker Vizio, Internet giant GoDaddy, rental car ...
... Sept. 11 During its 2009 Annual Conference in Washington, DC from ... some of the most pressing issues facing private care registries in the ... Conference include: , , , ... The program will cover PCA,s actions in the effort to ...
... , , , ... TD, pass completion , , CHICAGO, Sept. 11 ... Bears quarterback Jay Cutler means rooting for kids with diabetes. , ... Association (ADA) announced today they,re teaming up to help send children with ...
... , , , ... after bed bugs were believed to be exterminated nationwide, the teeny, ... proportions. , , They,re being spotted in ... motels, but posh resorts and upscale chains. In a recent study ...
Cached Medicine News:Health News:Bupa Launches its 2009 International Charity Challenge to Help a Rural Community in Ecuador 2Health News:Blue Cross Blue Shield of Michigan and Blue Care Network Announce Interim Policy to Cover H1N1 Vaccine Administration for Fully-Insured Groups During 2009-2010 Flu Season 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 3Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 4Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 5Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 6Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 7Health News:Private Care Association to Tackle Major Issues Impacting Home Care Industry 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 3Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 4Health News:Rest Easy, the Safe, All-Natural Bed Bug Travel Spray 2
... unique combination of topography, auto-refraction and keratometer ... three devices. The compactness of this instrument ... perfect space and cost saving solution. ... examination time and easy handling makes working ...
... SP-3000 covers all needs regarding pachymetry in ... care., ,Compact design, colored touch-screen and "quick ... an "easy-to-use unit.,The wide measurement range from ... the possibility to measure very thin or ...
The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
... Wave combines three advanced technologies - ... easy-to-use refractive diagnostic workstation. Now, with ... refraction, corneal topography, optical path difference ... Wave allows you to evaluate your ...
Medicine Products: